These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 24620417)

  • 1. A patent extension proposal to end the underrepresentation of women in clinical trials and secure meaningful drug guidance for women.
    Hathaway C
    Food Drug Law J; 2012; 67(2):143-76, i. PubMed ID: 24620417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Females in clinical studies: where are we going?
    Uhl K; Parekh A; Kweder S
    Clin Pharmacol Ther; 2007 Apr; 81(4):600-2. PubMed ID: 17314925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent reform in the US: what's at stake for pharmaceutical innovation?
    Yancey A; Stewart CN
    Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraceptive development and clinical trials.
    Fraser IS
    Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
    Fed Regist; 1998 Mar; 63(44):11174-7. PubMed ID: 10177511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
    Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent first, ask questions later: morality and biotechnology in patent law.
    Bagley MA
    William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation programs for pediatric drug research--do children really benefit?
    Boots I; Sukhai RN; Klein RH; Holl RA; Wit JM; Cohen AF; Burggraaf J
    Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programme.
    Nelson RE; McAdam-Marx C; Evans ML; Ward R; Campbell B; Brixner D; Lafleur J
    Appl Health Econ Health Policy; 2011 May; 9(3):171-81. PubMed ID: 21506623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do patents impede the provision of genetic tests in Australia?
    Nicol D; Liddicoat J
    Aust Health Rev; 2013 Jun; 37(3):281-5. PubMed ID: 23702081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action alert: drug-patent bill could cost patients $3 billion+; hearing July 1.
    AIDS Treat News; 1999 Jun; (No 321):8. PubMed ID: 11366716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations of sex and gender differences in preclinical and clinical trials.
    Raz L; Miller VM
    Handb Exp Pharmacol; 2012; (214):127-47. PubMed ID: 23027449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.